药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Trilostane
Pazufloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pazufloxacin.
Trilostane
Bilastine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Bilastine.
Trilostane
Difloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Difloxacin.
Trilostane
Sarafloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Sarafloxacin.
Trilostane
Phosmet
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Phosmet.
Trilostane
Orbifloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Orbifloxacin.
Trilostane
Fenthion
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fenthion.
Trilostane
Famphur
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Famphur.
Trilostane
Dichlorvos
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dichlorvos.
Trilostane
Coumaphos
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Coumaphos.
Trilostane
Acrivastine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Acrivastine.
Trilostane
Flumequine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Flumequine.
Trilostane
Chlorcyclizine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Chlorcyclizine.
Trilostane
Eribulin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Eribulin.
Trilostane
Geranylgeranyl diphosphate
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Geranylgeranyl diphosphate.
Trilostane
Farnesyl diphosphate
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Farnesyl diphosphate.
Trilostane
Triptorelin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Triptorelin.
Trilostane
Histrelin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Histrelin.
Trilostane
Buserelin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Buserelin.
Trilostane
Degarelix
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Degarelix.